2024

From Engineering to Operations: Addressing Pharma Challenges by Digital Approaches

by cyb2025

MARTIN MAYER1* , SELMA CELIKOVIC2, JAKOB REHRL3
*Corresponding author
1. ZETA GmbH, Werndorf, Austria
2. Research Center Pharmaceutical Engineering GmbH; Institute of Automation and Control, Graz University of Technology, Graz, Austria
3. Department of Information Technologies and Digitalisation, Salzburg University of Applied Sciences, Austria; Research Center Pharmaceutical Engineering GmbH

ABSTRACT

The article focuses on the challenges of the pharmaceutical industry that are closely linked to the production process, covering engineering, scale-up, technology transfer and operations. It covers digital, modeling- and simulation-based approaches to overcome these hurdles. The use of digital platforms allows for the collection and harmonization of vast amounts of data from various sources and consistent data integration. Model-based technologies are key for simulations and many optimization measures. Using models for optimization (e.g.: Model predictive control (MPC)) are up-and-coming methods for improving biopharmaceutical manufacturing systems. It is investigated whether the bioprocess models generated in a QbD/DoE approach can also be used online for operational support.

Introduction
The challenges the pharmaceutical industry is facing are manifold. They include high research and development costs, long development timelines, complex regulatory requirements, supply chain vulnerabilities, an enormous market competition and an increasing scrutiny on drug prices. Leveraging digital strategies such as artificial intelligence, machine learning, data analytics and blockchain technology holds significant promise in addressing many of
these difficulties.
This article focuses on the challenges of the pharmaceutical industry that are closely linked to the production process, covering engineering, scale-up, technology transfer and operations. Digital, modeling- and simulation-based approaches are to provide answers to prominent hurdles in the following areas:

 

Engineering and equipment design: Selecting and designing equipment that meets the specific requirements of the process and the regulatory standards of the pharma industry is complex. It goes hand in hand with optimizing the layout of the facility, to provide a safe production environment and enable an efficient workflow. The interdependencies of the core process and the utilities are complex, options for future expansions must also be taken into consideration.
Effective technology transfer: Bringing biotechnological production from the laboratory to an industrial scale is an extremely challenging task, as upscaling the process to production scale involves numerous technological challenges and substantial commercial risks. Technology transfer requires a planned approach with the appropriate documentation, data and information covering all aspects of development, production, and quality control, considering the regulatory requirements (1).

Process optimization and quality control: Due to the high complexity of pharmaceutical manufacturing, it is not a simple task to maintain optimal process efficiency and product quality. The availability of data plays a significant role in process optimization.

ABOUT THE AUTHOR

Martin Mayer has held a variety of senior roles spanning over 15 years in the international arena. Combining software and process expertise, Martin has honed his strategic and business skills to develop sustainable solutions for a diverse range of industries. His primary focus has been on digitalization, industrial IoT, machine learning applications, data management, data analytics, and model-based optimization (DoE) in both manufacturing and laboratory/R&D environments. In 2022, he assumed the position of Business Line Director for ZETA’s Digital Solutions Business Line.

Login